MarketCap
Facebook
X
TelegramAnnual report 2024
added 03-21-2026
Nymox Pharmaceutical Corporation Operating Cash Flow 2011-2026 | NYMX
Annual Operating Cash Flow Nymox Pharmaceutical Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -9.82 M | -10 M | -7.43 M | -7.8 M | -6.21 M | -4.5 M | -3.75 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -3.75 M | -10 M | -7.08 M |
Quarterly Operating Cash Flow Nymox Pharmaceutical Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -4.21 M | - | - | - | -2.67 M | - | - | - | -2.17 M | - | - | - | -1.59 M | - | - | - | -1.83 M | - | - | - | -740 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -740 K | -4.21 M | -2.2 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K |  USA |
 |
AbbVie
ABBV
|
19 B | $ 208.84 | -2.86 % | $ 369 B | USA |
 |
AbCellera Biologics
ABCL
|
-131 M | $ 3.52 | 0.28 % | $ 1.05 B |  Canada |
 |
Grifols, S.A.
GRFS
|
597 M | $ 8.24 | -0.12 % | $ 6.83 B |  Spain |
 |
Ascendis Pharma A/S
ASND
|
-418 M | $ 229.25 | 0.44 % | $ 5 B |  Danmark |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | France |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
ANI Pharmaceuticals
ANIP
|
64 M | $ 74.21 | -2.3 % | $ 1.43 B | USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-284 M | $ 1.41 | 2.17 % | $ 375 M | Britain |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
Cocrystal Pharma
COCP
|
-8.19 M | $ 1.51 | 48.04 % | $ 17 M | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
828 M | $ 55.5 | -3.04 % | $ 10.6 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-19.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-74.3 M | $ 8.03 | 2.29 % | $ 220 M |  Israel |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-46 M | $ 14.81 | 2.63 % | $ 2.25 B | USA |
 |
Altimmune
ALT
|
-67.5 M | $ 3.34 | 7.05 % | $ 294 M | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 91.18 | 1.97 % | $ 27.2 B | Germany |
 |
Amgen
AMGN
|
9.96 B | $ 347.94 | -1.51 % | $ 187 B | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
136 M | $ 15.61 | 0.9 % | $ 2.1 B | Canada |
 |
Bristol-Myers Squibb Company
BMY
|
14.2 B | $ 59.6 | -2.45 % | $ 121 B | USA |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Burford Capital Limited
BUR
|
181 M | $ 4.14 | -2.59 % | $ 683 M | Britain |
 |
BioCryst Pharmaceuticals
BCRX
|
-52 M | $ 9.02 | -3.84 % | $ 1.86 B | USA |
 |
Avenue Therapeutics
ATXI
|
-1.83 M | - | -52.27 % | $ 4.45 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-132 M | $ 5.76 | 1.95 % | $ 469 M | USA |
 |
BeiGene, Ltd.
BGNE
|
1.13 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Cellectis S.A.
CLLS
|
-105 M | $ 3.41 | 1.19 % | $ 116 M | France |
 |
Biogen
BIIB
|
2.2 B | $ 177.34 | -3.5 % | $ 26 B | USA |
 |
Axcella Health
AXLA
|
-69.6 M | - | -16.42 % | $ 249 M | USA |
 |
Axon Enterprise
AXON
|
408 M | $ 412.81 | -2.54 % | $ 31.3 B | USA |